SYRE Spyre Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1636282 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-77.1%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-35.0%
ROA-32.9%
ROIC (approx.)-29.1%
Asset turnover—
Leverage & solvency
Liabilities / assets4.4%
Debt / equity0.00x
Current ratio27.40x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.94x
Accruals ratio-1.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $0 | $0 |
| R&D expense | $171.65M | $162.79M |
| SG&A expense | $47.91M | $45.78M |
| Operating income | -$209.56M | -$208.57M |
| Pretax income | -$155.22M | -$207.97M |
| Income tax | -$15,000 | $51,000 |
| Net income | -$155.20M | -$208.02M |
| EBITDA | -$209.56M | -$208.57M |
| EPS (diluted) | — | — |
| Balance sheet | ||
| Cash & equivalents | $85.72M | $89.42M |
| Short-term investments | $670.81M | $513.66M |
| Current assets | $777.78M | $608.47M |
| Total assets | $777.78M | $608.48M |
| Current liabilities | $58.69M | $54.06M |
| Total liabilities | $62.55M | $90.68M |
| Shareholders' equity | $715.24M | $517.80M |
| Shares outstanding | 78.19M | 60.26M |
| Cash flow statement | ||
| Operating cash flow | -$169.25M | -$157.41M |
| Capital expenditure | — | $0 |
| Free cash flow | — | -$157.41M |
| Investing cash flow | -$143.47M | -$353.29M |
| Financing cash flow | $309.02M | $410.91M |
| Depreciation & amortization | $0 | $0 |
| Stock-based compensation | $37.61M | $44.83M |
Free plan shows the latest 2 periods; Pro shows all 12 🔒
· This company does not report gross profit in XBRL.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.